Abstract:The Canadian Journal of Psychiatry, Ahead of Print. ObjectivesThe majority of patients with schizophrenia experience dramatic improvement in psychotic symptoms when treated with antipsychotic medication. Maintenance treatment can prevent relapses but problems with medication adherence limit effectiveness. Long-acting injectable antipsychotics (LAIs) provide an opportunity to establish adherence but challenges remain in ensuring that the dose selected is therapeutic. Therapeutic drug monitoring has not been established as valuable for LAIs in the maintenance treatment of schizophrenia. This exploratory study was undertaken to describe plasma paliperidone levels in outpatients treated with the LAI paliperidone palmitate and to determine whether paliperidone levels are associated with subjective experience on medication and side effects.MethodsTwenty-one outpatients with schizophrenia receiving treatment with LAI paliperidone consented to participation in this study. Blood samples were obtained for measurement of paliperidone and prolactin levels at the first visit. A second paliperidone level was obtained at the time of the next injection for 18 of the participants. Clinical rating scales were administered at the first visit to assess illness severity, attitudes regarding medication, subjective well-being and side effects.ResultsPaliperidone levels were highly correlated at the two time points (ρ = .85; P < .001). Mean paliperidone level at the first visit was 34.9 ng/ml and ranged from 5.1 to 73.9 ng/ml. Higher paliperidone levels were correlated with higher prolactin levels (ρ = 0.59, P < .01) and lower sexual desire (ρ = −.58, P < .01).ConclusionsWe demonstrated that paliperidone levels can be measured reliably in patients receiving LAI paliperidone. Higher plasma levels were associated with higher prolactin levels and reduced sexual desire but not with measures of subjective experience on medications or other side effects. Measurement of paliperidone levels in patients treated with paliperidone palmitate may have the potential to minimize the dose of medication prescribed and, in turn, the severity of sexual side effects.Plain Language Summary TitleCan the Dosing of Long-Acting Injectable Paliperidone for the Treatment of Schizophrenia Be Improved by Measuring Drug Levels?Plain Language SummaryWhy was the study done?Antipsychotic medications are able to make the hallucinations and delusional thoughts go away for most people who have schizophrenia. Providing the medication in the form of an injection that can be given every few weeks or months can help people with schizophrenia stay well. It can be hard to know what dose of the injectable antipsychotic paliperidone will be best for each person. If the dose is too low, symptoms will return. If the dose is too high, side effects can be difficult to tolerate. This exploratory study was done to see whether measuring the amount of paliperidone in the blood can be used to make sure that the dose is likely to be effective and well tolerated.What did the researchers do?People with schizophrenia who were being treated with the long-acting injectable paliperidone had their blood drawn to measure the level of medication just before they received their next injection. Researchers also measured the symptoms and side effects that participants were experiencing to see whether people who had higher levels of paliperidone in their blood had more side effects.What did the researcher find?Even at the same dose of medication, some people had very small amounts of medication in their blood and others had much higher amounts. People with higher amounts in their blood experienced less sexual desire.What do the findings mean?The amount of paliperidone in the blood is a better measure of how much medication a person is getting than the dose they are given. Measuring paliperidone blood levels may lead to lower doses with fewer sexual side effects. It may make it easier for people with schizophrenia to continue on medication and to stay well.

Clinical Correlates of Antipsychotic Plasma Levels with Long-Acting Paliperidone: Corrélats cliniques des concentrations plasmiques de palipéridone à libération prolongée

A Randomized, 13-Week Study Assessing the Efficacy and Metabolic Effects of Paliperidone Palmitate Injection and Olanzapine in First-Episode Schizophrenia Patients

Effects of paliperidone extended-release tablets (paliperidoneer) and olanzapine on metabolic profile, weight, insulin resistance and beta-cell function in schizophrenic patients: a randomized 12-week study

Clinical outcomes of paliperidone long-acting injection in patients with schizophrenia: a 1-year retrospective cohort study

Patient satisfaction with 6-month paliperidone palmitate versus other long-acting injectable antipsychotics

Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia

Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia A Randomized, Double-Blind, Multicenter Study

Long-Acting Injectable Second-Generation Antipsychotics in Seriously Ill Patients with Schizophrenia: Doses, Plasma Levels, and Treatment Outcomes

Plasma Concentrations of Intramuscular Paliperidone Palmitate and the Relationship Between the Dose and Clinical Safety

Experience with 6-month paliperidone palmitate in a mental health center: descriptive study in real clinical practice

Pharmacokinetics and Tolerability of Paliperidone Palmitate Injection in Chinese Subjects

A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone

Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia

A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients

Descriptive study of 100 patients with a diagnosis of psychosis treated with Paliperidone Palmitate 6-Month Long-Acting Injectable.

Impact of Paliperidone Palmitate One-Month Formulation on Relapse Prevention in Patients with Schizophrenia: A Post-Hoc Analysis of a One-Year, Open-Label Study Stratified by Medication Adherence.

Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil

Long-Term Outcomes of 6-Month Paliperidone Palmitate in Patients With Schizophrenia

Paliperidone palmitate 6-month formulation for the treatment of schizophrenia: a 14-month follow-up study

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies

Weight gain and metabolic screening in young people with early psychosis on long acting injectable antipsychotic medication (aripiprazole vs paliperidone)